Observational study finds neutrophil RNA abnormalities in 33 of 34 lupus patients — Evidence Review

Researchers have found that nearly all lupus patients in a recent study had abnormal RNA processing in neutrophils, possibly creating new immune targets and offering an alternative explanation for autoimmunity. Most related studies agree that neutrophil abnormalities and immune recognition of altered molecules are central to lupus, supporting the new findings from the original study.

• Several prior studies have established that lupus neutrophils display abnormal gene expression, altered cell death, and release immunostimulatory molecules, all of which may provoke immune responses similar to those described in the new study 1 2 11 12 13.
• Research has repeatedly found that lupus is characterized by immune cell diversity and dysfunction, including increased T and B cell clonality, abnormal cytokine profiles, and loss of immune tolerance, which aligns with the new study’s focus on abnormal antigen generation and recognition 6 7 8 10.
• The concept of “neoantigen” formation from abnormal RNA processing is an emerging area, and while previous studies mainly focused on DNA and protein antigens in lupus, some recent work highlights the pathogenic potential of RNA-containing immune complexes and NET-associated RNAs 3 5.

Study Overview and Key Findings

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with unclear triggers for immune self-attack. This new study is significant because it identifies a molecular abnormality—widespread RNA splicing errors in neutrophils—that is present in almost all lupus patients studied but absent in healthy controls. The discovery proposes a shift from the classic “loss of tolerance” hypothesis to a model in which immune cells respond to genuinely foreign-appearing molecules generated within the body, potentially explaining how autoimmunity is initiated.

Property	Value
Study Year	2026
Organization	La Jolla Institute for Immunology, University of Washington
Journal Name	Nature
Authors	Rayan Najjar, Xiaoxing Wang, Farheen Shaikh, Ning Wang, Ethan Le, Jie An, Mohammad Pourshamsi, Cecilia Mustelin, Fatemeh Moadab, Spencer Mirabile-Brightman, Leslie Montero, Karla S. Zavala, Vincent Gureghian, Gabriela Cervantes, Sadie J. Van den Bogaerde, Samir Adhikari, Mikhail V. Pogorelyy, Paul G. Thomas, Stephen P. Schoenberger, Tomas Mustelin
Population	Patients with systemic lupus erythematosus
Sample Size	n=34
Methods	Observational Study
Outcome	RNA processing abnormalities in neutrophils, immune response
Results	33 out of 34 lupus patients had neutrophil RNA abnormalities.

Literature Review: Related Studies

To identify relevant prior research, we searched the Consensus database, which indexes over 200 million scientific papers. The following search queries were used to gather studies for this literature review:

1. lupus neutrophil RNA abnormalities
2. immune cell differences lupus patients
3. neutrophil function systemic lupus erythematosus

Topic	Key Findings
What roles do neutrophil abnormalities play in lupus pathogenesis?	- Lupus patients exhibit distinct neutrophil subsets (e.g., low-density granulocytes) that produce proinflammatory cytokines, form NETs, and release immunostimulatory molecules, contributing to tissue damage and autoimmunity 1 2 11 12. - Neutrophil diversity and dysregulation are linked to clinical manifestations (e.g., vascular damage, nephritis), and specific gene expression patterns in neutrophils correlate with disease severity 2 4.
How do abnormal nucleic acids (DNA/RNA) from neutrophils trigger immune activation?	- NETs externalize both DNA and RNA, which can activate plasmacytoid dendritic cells and endothelial cells, leading to increased type I interferon production and inflammation 3 11 12. - RNA-containing immune complexes stimulate neutrophil activation through TLR8-dependent pathways, and targeting RNA recognition may offer therapeutic benefit 5.
What immune cell differences and dysfunctions are characteristic of lupus?	- SLE is marked by altered T and B cell functions, increased TCR/BCR clonality, expansion of autoreactive clones, and imbalances in helper/regulatory T cell subsets 6 7 8 10. - Multi-cell type gene expression studies reveal coordinated interferon responses, cross-talk between immune cells, and links between specific gene signatures and disease activity 6 9.
How do these processes relate to clinical features and potential biomarkers?	- Neutrophil gene expression signatures and scores associate with organ involvement (e.g., lupus nephritis), but their predictive power as biomarkers may be limited 4. - Neutrophil ferroptosis (regulated cell death) and NET formation contribute to disease manifestations and may be therapeutic targets 13.

What roles do neutrophil abnormalities play in lupus pathogenesis?

The current study’s identification of widespread RNA processing errors in lupus neutrophils builds on a large body of work recognizing neutrophil dysfunction as central to lupus pathogenesis. Previous research has described abnormal subsets (such as low-density granulocytes), enhanced NET production, and the release of immunostimulatory molecules by lupus neutrophils, all of which can exacerbate inflammation and tissue damage.

• Abnormal neutrophil subsets in lupus patients display heightened NET formation and release molecules that can directly harm the endothelium and stimulate immune responses 1 2.
• These neutrophil changes correlate with specific clinical features, including vascular complications and severity of organ involvement 2 4.
• The diversity and activation state of neutrophils appear to influence disease phenotype and activity 2.
• The new study extends this understanding by suggesting that RNA splicing errors in neutrophils may directly generate neoantigens, providing a specific molecular mechanism for immune activation in lupus 1 2 11 12 13.

How do abnormal nucleic acids (DNA/RNA) from neutrophils trigger immune activation?

A key theme in lupus research is the role of nucleic acids released from dying neutrophils in stimulating the immune system. Earlier studies focused on DNA-containing NETs and their ability to activate plasmacytoid dendritic cells. More recent work has shown that RNA released via NETs or in immune complexes can also drive inflammation through specific receptors.

• NETs from lupus neutrophils contain both DNA and RNA; these nucleic acids are recognized by dendritic and endothelial cells, triggering type I interferon responses and perpetuating inflammation 3 11 12.
• Small RNAs externalized in NETs, such as microRNAs, can engage toll-like receptors (e.g., TLR7, TLR8) and promote inflammatory signaling in target cells 3 5.
• The presence of RNA abnormalities in neutrophils, as described in the new study, may provide new “neoantigenic” targets for T and B cells, building on this established mechanism 3 5.
• Therapies targeting RNA sensing pathways or the removal of extracellular nucleic acids are being explored as potential strategies for lupus management 5.

What immune cell differences and dysfunctions are characteristic of lupus?

The new study’s findings about neoantigen-driven T and B cell activation align with a broad literature describing immune cell dysregulation in SLE. Previous studies have documented altered T cell subsets, increased autoreactive B and T cell clones, and cytokine imbalances.

• SLE patients exhibit expanded and biased TCR/BCR repertoires, increased clonality, and abnormal distribution of immune cell types (e.g., reduced naïve T cells, increased cytotoxic T cells) 6 10.
• Imbalances between inflammatory (Th17) and regulatory (Treg) T cell subsets, as well as altered cytokine profiles (e.g., elevated IL-17, IL-6), contribute to disease activity and autoimmunity 7 8.
• Multi-cell type analyses have identified coordinated gene expression programs (e.g., interferon response) and cross-talk between immune cells, which are associated with disease severity and potential therapeutic targets 6 9.
• The concept that lupus autoimmunity may arise from immune recognition of truly abnormal self-molecules (neoantigens) rather than mere loss of tolerance builds on these findings 6 7 8 9.

How do these processes relate to clinical features and potential biomarkers?

Linking underlying molecular changes to clinical outcomes remains a challenge in lupus research. Several studies have evaluated the potential of neutrophil gene signatures, cell death pathways, and immune profiles as biomarkers or therapeutic targets.

• Neutrophil gene expression signatures are associated with lupus nephritis and disease activity, but their utility as reliable clinical biomarkers is limited by variability and confounding factors (e.g., steroid use) 4.
• Neutrophil ferroptosis, a regulated form of cell death, has been implicated as a driver of autoimmunity and disease manifestations in lupus, suggesting possible new treatment approaches 13.
• The identification of specific molecular processes (such as abnormal RNA splicing) may help refine biomarker development and targeted therapies 4 13.
• While many molecular signatures have been linked to particular lupus phenotypes, more research is needed to validate them as predictive or prognostic markers 4 13.

Future Research Questions

Although the new study provides novel insights into the molecular mechanisms of lupus, important questions remain unanswered. Further research is needed to clarify the timing and causality of RNA abnormalities, their relationship to disease activity, and their potential as therapeutic targets or biomarkers.

Research Question	Relevance
Do RNA splicing errors in neutrophils drive the initiation of lupus or arise as a consequence of disease?	Understanding the sequence of molecular events is critical for determining causality and targeting early disease processes 1 2 13.
Can neoantigens from abnormal RNA processing be used as biomarkers for diagnosis or disease monitoring in lupus?	Identifying reliable biomarkers could improve disease management; current neutrophil gene signatures have limited predictive power 4 13.
How do RNA-derived neoantigens activate T and B cells compared to DNA or protein autoantigens in SLE?	Elucidating the relative importance of different autoantigen types could inform therapy selection and disease mechanism models 3 5 11 12.
Can targeting RNA processing errors or neoantigen presentation reduce autoimmune activity in lupus?	Exploring new therapeutic approaches could lead to treatments that more precisely address the root causes of SLE autoimmunity 5 13.
Are similar RNA splicing abnormalities and neoantigen formation present in other autoimmune diseases?	Investigating this question may reveal broader mechanisms of autoimmunity and potential shared therapeutic targets 6 9.